Research Teams, Chair and projects
TEG - "The Entrepreneurial Garden" – Research team on Entrepreneurial Ecosystems – Sophie Reboud Coordinator
This research team has existed since 2013 and comes from a former wider team called ICE (Innovation, Clustering and Entrepreneurship).
TEG research focuses on entrepreneurship, its context and stakeholders. Following faculty is involved: Dr Alexandre Asselineau, Dr Valérie Ballereau, Dr Matthieu Claude Chaboud, Dr Jean-Guillaume Ditter, Dr Sabine Mueller, Dr Sophie Reboud and Dr Olivier Toutain.
The team is dedicated to the study of various aspects of Entrepreneurial Ecosystems, in other words, specific conditions in a context enabling new firms and small firms development. This includes following research topics:
- Stakeholders involved: small firms owner managers, potential entrepreneurs, creators, managing or taking over, students, support agencies, policy makers, educators and coachs
- Actions studied: decision making process, networking, education, local resources, individual and collective strategies, management of small firms and entrepreneurial teams
- Level of analysis: country, local territory, cluster, firm, person, learning space
This general research orientation is in line with the School's mission and development.
Read more about TEG Team http://theentrepreneurialgarden.eu/?lang=en
- MECIC team "Management of Cultural Organisations and Creative Industry" coordinate by Christine Sinapi
- LESSAC (Laboratory for Experimentation in Social sciences and Consumer behaviour) directed by Angela Sutan
The Laboratory for Experimentation in Social Sciences and Consumer Behaviour (LESSAC) has three missions:
- To develop the skills of professionals in the fields of marketing, human resources and economics
- To develop applied research through experimental projects on business issues
- To provide students of the school with an innovative and high-quality educational tool
Inaugurated in May 2008, the LESSAC centralises the experimental economics activities of the school, in order to explore all of the dimensions of decision-making, in the context of consumption, in the context of management or in the context of individual choice. The results produced can provide a quality response to the challenges of decision making that companies have to face.
Read more about LESSAC (in French) http://lessac.escdijon.eu/
- Corporate governance chair coordinated par Isabelle Allemand and financed by the "Crédit Agricole Champagne-Bourgogne" and "Crédit Agricole Franche-Comté" and the "Association des Femmes Diplômées d'Expertise Comptable Administrateurs"
The financial crisis has brought to light the necessity for firms to have a high quality of governance to improve their financial health. Firms should have a fair vision of the actors taking part in its governance: board of directors, shareholders, other stakeholders. Who are the decision-makers? Do firms have a clear definition of responsibilities? How does information flow between the different actors? How is the governance perceived by the stakeholders of the firm? Are the chosen accounting methods efficient? Is the financial communication clear, transparent and sincere? The financial crisis also reminds us of the high importance of risk management which should be in constant evolution.
The research team in governance has several targets:
- to contribute to the scientific community, with national and international research projects,
- to conduct analyses for practitioners and to help companies in their reflection on governance,
- to enhance the School teaching programs by motivating students towards questions of governance.
The chair members are Isabelle Allemand, Odile Barbe, Guillaume Biot-Paquerot, Bénédicte Brullebaut, Laurent Didelot, Fabrice Galia, Sophie Raimbaut and Emmanuel Zenou.
Read more about corporate governance chair http://www.bsbu.eu/faculty-research/research-in-corporate-governance-team/
- Microfinance chair coordinated by Arvind Ashta and financed by the "Banque Populaire de Bourgogne Franche Comté" and the "Fédération Nationale des Banques Populaires"
Micro-Finance sits at the crossroads of two fundamental dimensions of the school’s mission: entrepreneurial management and social responsibility. In addition to this, Burgundy School of Business can also be proud of its expertise on finance issues. The creation of a Chair in Micro-Finance in April 2009 was the culmination of a project that has enabled the school to become a leader in France in this domain with regard to research, teaching and to action in the field.
The chair members are Hayyan Alia, Arvind Ashta, Djamchid Assadi, Laurence Attuel-Mendès, Cornelia Caseau and Franck Lentz.
Read more about microfinance chair http://www.bsbu.eu/faculty-research/microfinance-chair/
- Responsible Management and Innovation (MIR) coordinate by Marc Ingham et financed by the Groupe La Poste
- The chair of Evaluation of the Medical claims of health food directed by Pr François-André Allaert
The agreement that led to the creation of the EMMAS (The Evaluation of the Medical Claims of Health Foods) Chair involving the first founding companies was signed for three years in February 2008 with CENBIOTECH. Several companies have since joined the Chair. The agreement specifies the objectives of the Chair: to carry out research in collaboration with companies and institutions that are interested in the development and evaluation of new health-related products, evaluate new health-related behaviour of patients/consumers. The work will focus on four main axes:
- The design of specific methodologies to assess the health claims of foods, dietary supplements and food supplements; the verification of claims has become compulsory under European legislation
- The development of pharmaco-epidemiological studies and the post-registration of medicines and medical devices that have obtained market approval, to determine the real medical benefit in everyday clinical and pharmaceutical practice
- Socio-demographic and hedonic factors in food choices made by consumers.
- The changing behaviour of the patient/consumer in the face of modifications in access to medical products and services: generic medicines, products that are no longer reimbursed, non-reimbursed medical fees and the evolution in medical demographics.